Ameriprise
CORT icon

Ameriprise’s Corcept Therapeutics CORT Stock Holding History

Ameriprise’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.55M Sell
212,074
-199,096
-48% -$7.44M ﹤0.01% 2035
2025
Q4 		$14.3M Buy
411,170
+188,794
+85% +$14.8M ﹤0.01% 1654
2025
Q3 		$18.5M Sell
222,376
-196,807
-47% -$14.2M ﹤0.01% 1456
2025
Q2 		$30.8M Buy
419,183
+154,602
+58% +$11.2M 0.01% 1114
2025
Q1 		$34.8M Sell
264,581
-52,737
-17% -$3.21M 0.01% 1020
2024
Q4 		$16M Sell
317,318
-74,955
-19% -$3.93M ﹤0.01% 1486
2024
Q3 		$18.2M Buy
392,273
+39,152
+11% +$1.39M ﹤0.01% 1391
2024
Q2 		$11.5M Buy
353,121
+60,221
+21% +$1.65M ﹤0.01% 1628
2024
Q1 		$7.38M Buy
292,900
+18,060
+7% +$427K ﹤0.01% 2062
2023
Q4 		$8.93M Sell
274,840
-21,461
-7% -$589K ﹤0.01% 1881
2023
Q3 		$8.07M Sell
296,301
-26,110
-8% -$756K ﹤0.01% 1881
2023
Q2 		$7.17M Sell
322,411
-40,367
-11% -$929K ﹤0.01% 2065
2023
Q1 		$7.86M Sell
362,778
-10,910
-3% -$239K ﹤0.01% 1964
2022
Q4 		$7.59M Sell
373,688
-13,109
-3% -$329K ﹤0.01% 1978
2022
Q3 		$9.92M Sell
386,797
-10,529
-3% -$282K ﹤0.01% 1685
2022
Q2 		$9.45M Sell
397,326
-3,574
-0.9% -$77.9K ﹤0.01% 1792
2022
Q1 		$9.03M Sell
400,900
-1,558
-0.4% -$33.1K ﹤0.01% 1995
2021
Q4 		$7.97M Sell
402,458
-37,141
-8% -$753K ﹤0.01% 2152
2021
Q3 		$8.65M Sell
439,599
-20,473
-4% -$428K ﹤0.01% 1971
2021
Q2 		$10.1M Sell
460,072
-10,483
-2% -$233K ﹤0.01% 1935
2021
Q1 		$11.2M Buy
470,555
+24,585
+6% +$656K ﹤0.01% 1784
2020
Q4 		$11.7M Sell
445,970
-15,644
-3% -$330K ﹤0.01% 1633
2020
Q3 		$8.04M Sell
461,614
-21,372
-4% -$341K ﹤0.01% 1717
2020
Q2 		$8.12M Sell
482,986
-18,153
-4% -$255K ﹤0.01% 1686
2020
Q1 		$5.96M Sell
501,139
-26,450
-5% -$327K ﹤0.01% 1786
2019
Q4 		$6.38M Sell
527,589
-15,686
-3% -$218K ﹤0.01% 2074
2019
Q3 		$7.68M Sell
543,275
-57,240
-10% -$703K ﹤0.01% 1898
2019
Q2 		$6.7M Sell
600,515
-15,601
-3% -$174K ﹤0.01% 2024
2019
Q1 		$7.23M Sell
616,116
-13,011
-2% -$162K ﹤0.01% 1959
2018
Q4 		$8.4M Sell
629,127
-2,815
-0.4% -$37.2K ﹤0.01% 1736
2018
Q3 		$8.86M Buy
631,942
+67,706
+12% +$946K ﹤0.01% 1962
2018
Q2 		$8.87M Sell
564,236
-286,267
-34% -$4.98M ﹤0.01% 1838
2018
Q1 		$14M Sell
850,503
-1,565
-0.2% -$29K 0.01% 1380
2017
Q4 		$15.4M Buy
852,068
+550,373
+182% +$9.97M 0.01% 1265
2017
Q3 		$5.82M Buy
+301,695
New +$4.5M ﹤0.01% 1988
2017
Q1 		– Sell
-116,360
Closed -$844K – 3617
2016
Q4 		$844K Buy
+116,360
New +$912K ﹤0.01% 3037
2013
Q4 		– Sell
-3,318
Closed -$5K – 5185
2013
Q3 		$5K Hold
3,318
– – ﹤0.01% 5226
2013
Q2 		$6K Buy
+3,318
New +$5.96K ﹤0.01% 5062

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Ameriprise's CORT Position: Q1 2026 in Review

Ameriprise reduced its Corcept Therapeutics (CORT) stake by 48% in Q1 2026, selling an estimated $7.44M and leaving 212,074 shares worth $8.55M. The position accounts for ﹤0.01% of the portfolio, ranked #2035.

Ameriprise first reported a position in CORT in Q2 2013 and has held it in 38 quarters since. The position peaked at $34.8M in Q1 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Ameriprise held 212,074 shares of Corcept Therapeutics worth $8.55M as of Q1 2026.
  • Ameriprise sold 199,096 Corcept Therapeutics shares in Q1 2026, an estimated $7.44M.
  • Corcept Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2035 holding.
  • Ameriprise first reported a position in Corcept Therapeutics in Q2 2013 and has held it in 38 quarters since.
  • Ameriprise's Corcept Therapeutics position peaked at $34.8M in Q1 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.